Skip to Content

For important updates on recent policy changes, please click here for more details.

Merck
CN
All Photos(1)

Key Documents

Safety Information

EHU034971

Sigma-Aldrich

MISSION® esiRNA

targeting human SERPINE2

Sign Into View Organizational & Contract Pricing

Select a Size

20 μG
CN¥3,096.05
50 μG
CN¥5,521.27

CN¥3,096.05

Estimated to ship onJuly 01, 2025Details

All Photos(1)

Select a Size

Change View
20 μG
CN¥3,096.05
50 μG
CN¥5,521.27

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

CN¥3,096.05

Estimated to ship onJuly 01, 2025Details

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGCTGAAAGTTCTTGGCATTACTGACATGTTTGATTCATCAAAGGCAAATTTTGCAAAAATAACAACAGGGTCAGAAAACCTCCATGTTTCTCATATCTTGCAAAAAGCAAAAATTGAAGTCAGTGAAGATGGAACCAAAGCTTCAGCAGCAACAACTGCAATTCTCATTGCAAGATCATCGCCTCCCTGGTTTATAGTAGACAGACCTTTTCTGTTTTTCATCCGACATAATCCTACAGGTGCTGTGTTATTCATGGGGCAGATAAACAAACCCTGAAGAGTATACAAAAGAAACCATGCAAAGCAACGACTACTTTGCTACGAAGAAAGACTCCTTTCCTGCATCTTTCATAGTTCTGTTAAATATTTTTGTACATCGCTTCTTTTTCAAAACTAGTTCTTAGGAACAGACTCGATGCAAGTGTTTCTGTTCTGGGAGGTATTGGAGGGAAAAAACAAGCAGGATGGCTG

Ensembl | human accession no.

ENSG00000135919

NCBI accession no.

NM_006216

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... SERPINE2(5270) , SERPINE2(5270)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
EHU090971EHU016891EHU005301
MISSION® esiRNA targeting human SERPINE2

EHU034971

MISSION® esiRNA

MISSION® esiRNA targeting human SERPINA1

EHU090971

MISSION® esiRNA

MISSION® esiRNA targeting human SERPINE1

EHU016891

MISSION® esiRNA

MISSION® esiRNA targeting human SERPINI2

EHU005301

MISSION® esiRNA

esiRNA cDNA target sequence

CGCTGAAAGTTCTTGGCATTACTGACATGTTTGATTCATCAAAGGCAAATTTTGCAAAAATAACAACAGGGTCAGAAAACCTCCATGTTTCTCATATCTTGCAAAAAGCAAAAATTGAAGTCAGTGAAGATGGAACCAAAGCTTCAGCAGCAACAACTGCAATTCTCATTGCAAGATCATCGCCTCCCTGGTTTATAGTAGACAGACCTTTTCTGTTTTTCATCCGACATAATCCTACAGGTGCTGTGTTATTCATGGGGCAGATAAACAAACCCTGAAGAGTATACAAAAGAAACCATGCAAAGCAACGACTACTTTGCTACGAAGAAAGACTCCTTTCCTGCATCTTTCATAGTTCTGTTAAATATTTTTGTACATCGCTTCTTTTTCAAAACTAGTTCTTAGGAACAGACTCGATGCAAGTGTTTCTGTTCTGGGAGGTATTGGAGGGAAAAAACAAGCAGGATGGCTG

esiRNA cDNA target sequence

ACTGTCAACTTCGGGGACACCGAAGAGGCCAAGAAACAGATCAACGATTACGTGGAGAAGGGTACTCAAGGGAAAATTGTGGATTTGGTCAAGGAGCTTGACAGAGACACAGTTTTTGCTCTGGTGAATTACATCTTCTTTAAAGGCAAATGGGAGAGACCCTTTGAAGTCAAGGACACCGAGGAAGAGGACTTCCACGTGGACCAGGTGACCACCGTGAAGGTGCCTATGATGAAGCGTTTAGGCATGTTTAACATCCAGCACTGTAAGAAGCTGTCCAGCTGGGTGCTGCTGATGAAATACCTGGGCAATGCCACCGCCATCTTCTTCCTGCCTGATGAGGGGAAACTACAGCACCTGGAAAATGAACTCACCCACGATATCATCACCAAGTTCCTGGAAAATGAAGACAGAAGGTCTGCCAGC

esiRNA cDNA target sequence

CTGGTTCTGCCCAAGTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGACATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTCGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCATCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCCTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATGGAACCCTGACCCTGGGGAAAGACGCCTTCATCTGGGACAAAACTGGAGATGCATCGGGAAAGAAGAAACTCCGAAGAAAAGAATTTTAGTGTTAATGACTCTTTCTGAAGGAAGAGAAGACATTTGCCTTTTGTTAAAAGATGGTAAACCAGATCTGTCTCCAAGACCTTGGCCTCTCCTTGGAGGACCTTT

esiRNA cDNA target sequence

CCAATGATGAAGGCTCTTCTGAGAACAAAATATGGTTATTTTTCTGAATCTTCCCTGAACTACCAAGTTTTAGAATTGTCTTACAAAGGTGATGAATTTAGCTTAATTATCATACTTCCTGCAGAAGGTATGGATATAGAAGAAGTGGAAAAACTAATTACTGCTCAACAAATCCTAAAATGGCTCTCTGAGATGCAAGAAGAGGAAGTAGAAATAAGCCTCCCTAGATTTAAAGTAGAACAAAAAGTAGACTTCAAAGACGTTTTGTATTCTTTGAACATAACCGAGATATTTAGTGGTGGCTGCGACCTTTCTGGAATAACAGATTCATCTGAAGTGTATGTTTCCCAAGTGACGCAAAAAGTTTTCTTTGAGATAAATGAAGATGGTAGTGAAGCTGCAACATCAACTGGCATACACATCCCTGTGATCATGAGTCTGGCTCAAAGCCAATTTATAGCAAATCATCCATTTCTGTTTATTATGAAGCATAATCCAACAGAATCAATTCTGTTTATGGGAAGAGTGACAAATCCTGACACCCAGGA

Ensembl | human accession no.

ENSG00000135919

Ensembl | human accession no.

ENSG00000197249

Ensembl | human accession no.

ENSG00000106366

Ensembl | human accession no.

ENSG00000114204

product line

MISSION®

product line

MISSION®

product line

MISSION®

product line

MISSION®

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

NCBI accession no.

NM_006216

NCBI accession no.

NM_000295

NCBI accession no.

NM_000602

NCBI accession no.

NM_006217

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    QCS
    DOR

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    En-Dong Zhu et al.
    PloS one, 9(8), e106049-e106049 (2014-08-30)
    Gastric cancer is one of the most common malignant diseases worldwide. Emerging evidence has shown that microRNAs (miRNAs) are associated with tumor development and progression. Our previous studies have revealed that H. pylori infection was able to induce the altered
    Kun Wang et al.
    Journal of cancer research and clinical oncology, 141(5), 805-812 (2014-11-02)
    Altered expression of serine protease inhibitor peptidase inhibitor clade E member 2 (SERPINE2) associates with human cancer development and progression; thus, this study investigated SERPINE2 expression in gastric cancer tissues for association with clinicopathological and survival data from the patients
    Ruozhi Zhao et al.
    Journal of leukocyte biology, 95(6), 941-949 (2014-02-06)
    Diabetes mellitus accelerates the development of atherosclerotic cardiovascular diseases. Monocyte adhesion is an early cellular event of atherogenesis. Elevated levels of glyLDL were common in diabetic patients. Our previous studies indicated that HSF1 and p22-phox (a subunit of the NOX

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service